About STRM.BIO INCORPORATED
STRM.BIO is a biotechnology company focused on developing non-viral gene therapy delivery platforms using megakaryocyte-derived extracellular vesicles (STRM MVs) to target bone marrow and advance in vivo cell engineering and gene therapy. The company has received an ARPA-H contract to further develop its platform.
Development of non-viral gene therapy delivery platformsIn vivo delivery of genetic medicines using megakaryocyte-derived extracellular vesicles (STRM MVs)Gene editing, RNA therapeutics, and immune cell engineeringRepeat dosing capability with a non-viral, immune-privileged, allogeneic platformScalable manufacturing for clinical and commercial production
Is this your company?
Claim this profile to keep it accurate — and see the federal & state opportunities GovIntel's AI has matched to STRM.BIO INCORPORATED right now.
Claim this profile See matched opportunitiesData compiled from public government sources including SAM.gov, USAspending.gov, and state procurement records. Last verified against federal award records. Inaccurate? Let us know.